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Structural Basis of Outstanding Multivalent Effects in Jack bean 
α-Mannosidase Inhibition 
Eduardo Howard,‡[a,d] Alexandra Cousido-Siah,‡[a] Mathieu L. Lepage,[b] Jérémy P. Schneider,[b] Anne 
Bodlenner,[b] André Mitschler,[a] Alessandra Meli,[c] Irene Izzo,[c] Ariel Alvarez,[d] Alberto Podjarny,[a] 
Philippe Compain*[b]  
 
Abstract: Multivalent design of glycosidase inhibitors is a 
promising strategy for the treatment of diseases involving 
enzymatic hydrolysis of glycosidic bonds in carbohydrates. An 
essential prerequisite for successful applications is the atomic 
level understanding of how outstanding binding enhancements 
are actually achieved with multivalent inhibitors. Here we report 
the first high resolution crystal structures of the Jack bean-
mannosidase (JBα-man) in apo and inhibited states. The three-
dimensional structure of JBα-man in complex with the multimeric 
cyclopeptoid-based inhibitor displaying the largest binding 
enhancements reported so far provides decisive insights into the 
molecular mechanisms underlying multivalent effects in 
glycosidase inhibition.  
 
The modulation of the multiple biological activities of 
glycosidases is a major target for drug discovery.[1] Catalytic 
hydrolysis of glycosidic linkages, the most stable covalent single 
bonds within biopolymers, is indeed a fundamental process 
involved in key cellular events including energy uptake and post-
translational modifications of glycoproteins.[2] Multivalent design 
of glycosidase inhibitors has recently experienced a major take-
off with the disclosing of glycomimetic clusters showing 
outstanding affinity enhancements over the corresponding 
monovalent ligands (up to five orders of magnitude).[3-7] Although 
intensive efforts have been performed to rationalize the 
inhibitory multivalent effect observed, structural information into 
the way multimeric inhibitors and glycosidases interact at the 
atomic level remains unknown.[6] Recent studies in the field have 
logically focused on Jack bean -mannosidase (JBα-man) since 
this high-molecular-weight (220 kDa) zinc-enzyme,[8] is the most 
sensitive to multivalent binding known to date.[6] JBα-man is a 
member of the retaining glycoside hydrolase family 38 (GH38) 
that contains therapeutically relevant -mannosidases.[8] These 
mammalian enzymes participate to the biosynthesis and 
catabolism of N-glycan in cells[8b] and as such constitute targets 
for the treatment of cancers and lysosomal diseases.[9] In the 
absence of 3D crystallographic structure for JBα-man, 
interactions with multivalent inhibitors have been studied using 
indirect methods such as atomic force microscopy, dynamic light 
scattering, NMR or mass spectroscopy.[5-7] These studies have 
led to a number of competing hypotheses and binding models 
involving large aggregates, additional interactions with enzyme 
subsites or formation of discrete cross-linked complexes.[5-7] 
Here we report the first high-resolution crystal structures of apo 
JB-man and of its complex with the 36-valent cluster 1[7] 
(Figure 1). The experimental observation of multivalent 
interactions associated with molecular modelling suggests a 
clear rational basis for the outstanding affinity enhancement 
observed.  
 
 
Figure 1. Mono- and 36-valent inhibitors of JBα-man. Pr = propyl. 
The apo structure of JB-man was solved by X-ray protein 
crystallography at 1.84 Å resolution (Protein Data Bank -PDB- 
entry 6B9O). Molecular replacement with Bovine Lysosomal α-
Mannosidase (PDB entry 1O7D)[10] was successfully used for 
the initial structure determination. This protein was chosen 
following a sequence alignment of the published sequence for 
JB-man[8a] against the full PDB content, which gave 40% 
identity (Tables SI1 and Figure SI1 in the Supporting 
Information). The crystallographic asymmetric unit has one JB-
man protein composed by two LH heterodimers, each formed 
by the two distinct chains, L1 and H1 (L:Light chain and 
H:Heavy chain) (Figure 2). This figure shows also the symmetry 
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related (LH)2 complex (LH1a and LH2a). The four active sites, 
identified by the zinc ions in the H-chain, are turned toward a 
cavity at the center of the complex composed by the four LH 
heterodimers. We anticipated that this large pocket could fit the 
size of large multivalent inhibitors such as 1.   
 
Figure 2. Ribbon representation of two (LH)2 complexes, one formed by LH1 
(L1 in cyan and H1 in green) and LH2 (in red) and a symmetry related one 
formed by LH1a (in yellow) and LH2a (in blue),  and zinc atoms (grey sphere). 
How JB-man binds multimeric inhibitors is key to our analysis 
of the outstanding multivalent effects observed. To gain detailed 
insights at the atomic level, we attempted to determine the 
structures of complexes of JB-man with diverse cyclopeptoid-
based iminosugar clusters.[7] Extensive co-crystallization of 
enzyme:inhibitor complex was carried out by a Mosquito robot 
using sitting-drop vapor-diffusion method. Remarkably, well-
diffracting crystals were obtained with 1 which displays the 
largest binding enhancement observed so far for a glycosidase 
(Figure 1).[7] The 36-valent cluster 1 complex structure of JB-
man was solved by X-ray protein crystallography at 2.0 Å 
resolution (PDB entry 6B9P). The overall structure of this 
complex was similar to the apo form of JB-man with the same 
crystal parameters (space group and cell dimensions), indicating 
that multivalent inhibitor binding does not perturb the protein. 
The X-ray complex structure showed the mode of binding of four 
iminosugar heads of the 36-valent cluster 1 in the catalytic site 
of each LH heterodimer. In the X-ray structure, only one 
iminosugar head was clearly visible for each LH heterodimer in 
the electron density map at 2.0 Å resolution, suggesting the 
absence of a secondary binding site (Figure 3 and Figure SI2 in 
the Supporting Information). Non-specific interactions at the 
surface of the enzyme can, however, not be excluded. The 
iminosugar head of the multivalent inhibitor is buried in the 
catalytic pocket in the H-chain, while the aliphatic linker makes 
hydrophobic contacts with the protein surface (Figure 3 and 
Figures SI2-6 in the Supporting Information).  
 
Figure 3. JB-man protein structure in complex with iminosugar head and the 
aliphatic chain of 1; cyan ribbon L-chain, green ribbon H-chain, yellow sticks 
carbon atoms, red sticks oxygen atoms, blue sticks nitrogen atoms and zinc 
atom grey sphere. 
The zinc atom in the H-chain is clearly observed in an octahedric 
coordination with six atoms at distances between 2.1 Å and 2.3 
Å (Figure 4); four oxygen atoms, two of them provided by protein 
aspartate residues (Asp145, Asp25) and two by the iminosugar 
head, and two nitrogen atoms provided by protein histidine 
residues (His23 and His386). The geometry and the intervening 
residues are the same than in previously reported structures 
from two other proteins of the same GH38 family (Figure SI7 in 
the Supporting Information),[10-11] with the notable difference that 
the ligand in those previous structures provides only one zinc 
coordinating oxygen. The residue Asp145 is characteristic of 
GH38 α-mannosidases and has been demonstrated as the 
catalytic nucleophile in JBα-man.[12] Based on the expected 
distance (~ 5.5 Å) between the two catalytic carboxylate groups 
in retaining hydrolysis mechanism,[13] Asp25 would seem the 
most likely candidate for the catalytic acid/base (Figure SI6 in 
the Supporting Information). In addition, the involvement of the 
two catalytic residues in the coordination of the zinc ion is 
believed to be essential to the mechanism of the catalytic 
glycosidic cleavage.[10-11]  
 
Figure 4: Contacts of iminosugar head with protein and zinc atom. Protein in 
green sticks, 1 in yellow sticks, zinc atom grey sphere and two water 
molecules red sphere. Left: Full site. Right: Zoom on Zn coordination. 
No electron density could be observed beyond the quaternary 
carbon branching point of the trivalent dendron of cluster 1. 
Since the considerable conformational flexibility of the cyclic 
peptoid core and associated ethylene glycol spacers precludes a 
priori direct information from X-ray crystallography, a 3D model 
of the full 36-valent cluster 1 was built and was successfully 
fitted into the cavity with the program Coot[14] (Figure SI8 in the 
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Supporting Information). The iminosugar heads were kept in the 
positions shown in the X-Ray maps, the inhibitor core in the 
middle of the cavity and the remaining part between the core 
and the iminosugar heads in an arbitrary conformation. This 
encouraging result indicated that our binding model was 
sterically plausible. However, the absence of any signal 
corresponding to the disordered center of 1 in the electron 
density map at 2.0 Å prompted us to develop a convenient 
method to obtain experimental evidence for its location. A 
combination of symmetry lowering and low resolution maps 
eventually enabled us to observe a signal corresponding to the 
inhibitor core. Since the cavity spans two asymmetric units in 
P212121, with one half of the cavity in each asymmetric unit, the 
disordered multivalent ligand might not respect the symmetry 
between both halves. In order to recover any diffraction signal, 
the whole cavity should be in a single asymmetric unit. To do 
this, the symmetry of both crystals (apo and holo) was reduced 
from orthorhombic (P212121) to monoclinic (P21), expanding the 
asymmetric unit to include the two (LH)2 complexes. The 
corresponding structure factors were recalculated from the raw 
images to recover all the information present in the diffraction 
data. The corresponding models (apo and holo) were placed in 
the P21 space group and re-refined, giving a very similar result to 
the P212121 refinement for the protein. Maps were calculated in 
this new space group. As no high resolution details are expected, 
due to the flexibility of the multivalent ligand, map resolution was 
reduced from 2.0 Å to 5.0 Å, a suitable limit to enhance features 
of this size even with partial disorder. Electron density maps for 
the protein were very similar (Figure 5). However, a signal was 
observed at the center of the cavity only for the data from the 
crystal with the multivalent ligand 1, strongly suggesting the 
presence of its core. 
a) b)  
c)  
Figure 5: Electron density low resolution 2Fo-Fc map in blue (5 Å, 1.0 σ 
contour) and protein cartoon (yellow, blue, green and red). a) apo crystal; b) 
crystal with 1; c) Close up on the density at the center superposed with the 
model of cluster 1 (cyan).  
The conformational space of the multivalent ligand inside the 
cavity was explored with simulated annealing using the program 
Phenix,[15] starting from five different positions (generated 
manually with Coot[14]) for the linker arms and central core 
(Figure SI9 in the Supporting Information). In each of the five 
positions the same four heads were kept in the corresponding 
catalytic pockets. This led to five models clearly demonstrating 
that the four bound iminosugar heads belong to the same 
multivalent ligand. The observation of an electron density signal 
at the center of the cavity provides the experimental proof that 
this topology is the most probable one (Figure 5). The present 
structural study confirms the formation of a 2:1 JBα-man:inhibitor 
sandwich-type complex that was initially postulated on the basis 
of electron microscopy imaging, analytical ultracentrifugation 
measurements and mass spectroscopy experiments.[7]  
The experimental observation of multivalent interactions 
associated with molecular modelling suggests a clear rational 
basis for the high affinity enhancements observed in JB-man 
inhibition. In the binding topology proposed, the multivalent 
ligand occupies the cavity created by two (LH)2 complexes, with 
the core placed at the center of this cavity, radial arms pointing 
towards the four catalytic sites present in the H subunits and 
four iminosugar heads binding to them. The bridging of two (LH)2 
complexes by four iminosugar heads of the multimeric inhibitor 
results in a strong chelation effect explaining the exceptionally 
large affinity enhancements observed.[7] The chelation effect is 
indeed considered to be the mode of binding underlying the 
most powerful multivalent effects reported to date.[16] It is 
noteworthy that inhibitor 1 fully occupies the cavity. Reduced 
multivalent effects may be anticipated for smaller clusters able to 
embrace only two catalytic sites simultaneously, or for giant 
clusters that would not fit inside the cavity, leading to other 
binding modes.[4f-g,7] The iminosugars that are not buried in the 
catalytic pocket remain in close proximity, opening the possibility 
of multiple bind-and-recapture processes.[17]  
 
In conclusion, the first high-resolution crystal structures of apo 
JBα-man and of its complex with the 36-valent cluster 1 
considerable insights at the atomic level into the way a 
glycosidase and a multimeric inhibitor interact to produce 
outstanding inhibitory multivalent effects. The X-ray 
crystallographic structure showed four ordered iminosugar 
heads of the 36-valent cluster 1 simultaneously engaging all four 
active sites of two JBα-man molecules to form a strong 
sandwich chelate complex. The crystal structures presented 
here provide the foundations for a rational design of multivalent 
inhibitors targeting JBα-man and the related clinically relevant 
GH38 α-mannosidases.  
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